| |
|
|
|
|
|
|
|||
|
CHEMOKINES
From the Laboratory of Medical Allergology, Allergy
Unit, and the Laboratory for Tissue Typing, Department of Clinical
Immunology, National University Hospital, Denmark; and the
Department of Immunology, Anhui Medical University, People's
Republic of China.
CXC chemokine receptor 3 (CXCR3), which is known to be expressed
predominately on memory and activated T lymphocytes, is a receptor for
both interferon The trafficking of hematopoietic progenitor cells
occurs during mobilization and homing, which play a key role in
subsequent proliferation, differentiation, and maturation of these
cells. However, little is known about the mechanisms and molecules that regulate the homing, retention, and migration of hematopoietic progenitor cells in hematopoietic organs. Analogous with the processes in mature leukocytes, these processes likely involve chemoattractant molecules and their receptors, which are known to regulate the trafficking of leukocytes under both physiologic and pathologic conditions. The CXC chemokine receptor (CXCR) 3, a G-protein-coupled 7-transmembrane receptor, is expressed at high levels on activated and
memory T cells, B cells, natural killer cells, and plasmacytoid monocytes.1-3 It has also been shown to bind interferon
(IFN) Blood T cells expressing CXCR3 were mostly CD45RO+ and
generally expressed high levels of Purification of CD34+ hematopoietic progenitor
cells
Flow cytometry
Real-time quantitative reverse transcription-polymerase chain reaction (RT-PCR) assay All real-time quantitative RT-PCR reactions were performed as described elsewhere.13-15 Briefly, total RNA from CD34+ hematopoietic progenitor cells (1 × 106; purity > 99%) was prepared by using a Quick Prep total RNA extraction kit (Pharmacia Biotech, Uppsala, Sweden), and any potential contaminating chromosomal DNA was digested with DNAase I according to the manufacturer's instructions. The RNA was reverse transcribed by using oligo(dT)12-18 and Superscript II reverse transcriptase (Life Technologies, Grand Island, NY) according to the manufacturer's instructions. Reverse transcription was performed for 60 minutes at 37°C, and any potential contaminating protein was denatured by incubation for 10 minutes at 95° C. The real-time quantitative PCR was performed in special optical tubes in a 96-well microtiter plate (Perkin Elmer Applied Biosystems, Foster City, CA) by using a sequence detector system (ABI Prism 7700; Perkin Elmer Applied Biosystems) according to the manufacturer's instructions. An SYBR green PCR core reagents kit (Perkin Elmer Applied Biosystems) was used to generate fluorescence during each PCR cycle by means of the 5' to 3' endonuclease activity of AmpliTaq Gold13 to provide real-time quantitative PCR information. The CXCR3 genes were generated by connecting the following sequences of the specific primers (DNA Technology, Aarhus, Denmark): sense, 5'-GGAGCTGCTCAGAGTAAATCAC-3'; and antisense, 5'-GCACGAGTCACTCTCGTTTTC-3'.All unknown complementary DNAs (cDNAs) were diluted to contain equal
amounts of Northern blot analysis As previously described,16 total RNA from peripheral cells was prepared by using a Quick Prep total RNA extraction kit. Five micrograms of total RNA from each sample was electrophoresed under denaturing conditions, blotted on Nytran membranes (Schleicher & Schuell Inc, Keene, NH), and cross-linked by UV irradiation. cDNA probes were labeled with -phosphorus 32 (32P) deoxycytidine triphosphate. A CXCR3 cDNA probe was
obtained by PCR amplification of the sequence shown above from total
RNA of peripheral CD3+ T lymphocytes from healthy adults.
The membranes were hybridized overnight with 106 cpm/mL of
32P-labeled probe and then washed with 0.2 × SSC
(1 × SSC = 0.15 mol/L sodium chloride (NaCl) and 0.015 mol/L
sodium citrate [pH 7.0]) and 0.1% sodium dodecyl sulfate before
being autoradiographed.
In vitro chemotaxis assay As described by Kim and Broxmeyer,17 chemotaxis and chemokinesis were assayed by a modification of the checkerboard assay. Fifty microliters of chemotaxis buffer (RPMI 1640, 0.5% BSA, and antibiotics) suspended with 2 × 105 cells/mL was added to the upper well of the chamber, which was separated from the lower well by a polycarbonate, polyvinylpyrrolidone-free membrane (5 µm pore size) without a collagen coating (Nucleopore, Pleasanton, CA). Chemotaxis buffer was added to the lower chamber. Various amounts of chemoattractants were added to the chemotaxis buffer in the upper chamber, the lower chamber, or both, to form various chemoattractant concentration gradients to form various chemotactic gradients (positive gradient [0/+], negative gradient [+/0], and zero gradient [+/+ or 0/0]). All tests were performed in triplicate. Chambers were incubated at 37°C in 5% carbon dioxide (CO2) for 4 hours. Cells that migrated into the 3 lower chambers were collected and counted by using either a flow cytometer (Coulter XL) for 20 seconds at a high flow rate or a light microscope, by which identical results could be obtained. The cell migration was determined by calculating the percentage of input cells that migrated into the lower chamber.Colony-forming cell assays As described by Broxmeyer et al,18 migrated or input cells were plated at concentrations of about 300 CD34+ cells/mL in 35-mm plastic tissue-culture dishes (Nunc, Roskilde, Denmark) containing 1 U/mL recombinant human erythropoietin (EPO; Sigma Chemical Co, St Louis, MO), 100 U/mL GM-CSF, and 100 U/mL IL-3, with and without various chemokines, in 1% methylcellulose culture medium containing 30% fetal-calf serum (FCS). After 7 to 10 days of incubation, burst-forming units-erythroid (BFU-E), colony-forming units-granulocyte-macrophage (CFU-GM), and mixed-cell units (colony-forming units-granulocyte-erythroid-macrophage-megakaryocyte [GEMM]), which respectively identify erythrocyte, granulocyte-macrophage, and multipotential progenitor cells, were scored in situ with an inverted microscope by using standard criteria for their identification.19Adhesion assays Adhesion assays were performed as described previously.12 Briefly, 96-well microtiter plates were coated with laminin (20 µg/mL; Sigma Chemical Co) in PBS for 1 hour at 37°C in a humidified atmosphere. The plates were washed with PBS and incubated with medium containing 0.2% BSA for 1 hour in 5% CO2 to block nonspecific adhesion. Thereafter, single-cell suspensions were prepared in RPMI 1640 medium with 0.2% BSA (4 × 105 cells/mL), and IP-10, Mig, or chemokine
stromal cell-derived factor 1 (SDF-1 ) was added (100 ng/mL). The
cell suspension was added in triplicate to 96-well plates (100 µL per
well) and incubated for 60 minutes at 37°C. To remove nonadherent
cells, an 8-tipped manifold was used to aspirate all but about 50 µL of liquid from the wells by suspending the manifold at a uniform distance from the bottom of each well. The wells were then washed by
carefully directing a stream of 0.2% BSA in PBS along the sides of the
wells with the 8-tipped manifold after aspiration. Subsequently, the
adherent cells were fixed with 1% formaldehyde and stained with 1%
crystal violet. The crystal violet was then extracted by adding a 1:1
mixture of 0.1 mol/L sodium citrate (pH 4.2) and ethanol, and
absorbency was read at 540 nm. Cells bound to collagen I (10 µg/mL)
on separate wells were used to represent 100% attachment. Background
cell adhesion to 2% BSA-coated wells was subtracted from all readings.
For inhibition assays, cells were preincubated with different
antibodies at 4°C for 30 minutes before the assay.
Aggregation assays Aggregation assays were performed as described previously.12,20 Briefly, the cells were added at a concentration of 106/mL to culture plates with 24 wells. The chemokines were added to RPMI 1640 culture medium with 10% FCS. After 24 hours, the cells were observed, scored, and photographed by using a Leitz microphotography system. The following semiquantitative scoring method12,20 was used: 0, no aggregation; 1+, less than 10% of cells aggregated; 2+, more than 50% of cells aggregated; 3+, up to 90% of cells small, loose clusters; and 4+, more than 90% of cells aggregated in large clusters.Polarization assay and immunofluorescence digital confocal microscopy Immunofluorescence experiments were performed as described elsewhere.21 Briefly, chemokines (100 ng/mL) were used in RPMI 1640 culture medium with 10% FCS in chemotaxis assays. The GM-CSF-stimulated CD34+ hematopoietic progenitor cells were added at a concentration of 106/mL to a chemotactic chamber. After assay, the migrated GM-CSF-stimulated CD34+ cells were collected and spun down on a slide, fixed with a mixture of methanol and acetone, and immersed in 1% BSA blocking buffer for 10 minutes to avoid nonspecific binding. Primary antibody, either anti-CXCR3 mAb (49801.111 [10 µg/mL]; R&D Systems Europe Ltd) or with isotype IgG1 (10 µg/mL), was added, and after incubation overnight at 4°C, secondary FITC-labeled donkey antimouse antibody (1:250 vol/vol; Jackson ImmunoResearch Laboratories Inc, West Grove, PA) was added. Cells were observed with a fluorescence microscope (BX60; Olympus, Japan). Confocal microscopy analysis was performed with a confocal laser scanning system and an inverted microscope (LSMSIO; Zeiss, Germany). Images of serial cellular sections were acquired with a graphical user interface (Comos; Bio-Rad, Hercules, CA) as described previously.21
Expression of CXCR3 on CD34+ progenitors is induced by GM-CSF Flow cytometric analyses (Figure 1) showed only rare CXCR3+ cell fractions in freshly isolated CD34+ progenitors from cord blood (<3%; Figure 1B). After 36 hours of incubation with cytokine-free medium, there was no significant change in the CXCR3+ cell fraction (data not shown). Interestingly, 10 ng/mL of GM-CSF significantly up-regulated the expression of CXCR3 on CD34+ progenitors up to 97.6% (Figure 1C). Moreover, CXCR4 was constantly expressed in both freshly isolated CD34+ progenitors (96.9%; Figure 1E) and GM-CSF-stimulated CD34+ progenitors (98.2%; Figure 1F). Figures 1A and 1B show the results with the isotype controls for anti-CXCR3 and anti-CXCR4 antibodies, respectively.
In the kinetic study shown in Figure 2, a
slightly increased expression (about 15.7%) of CXCR3 on
GM-CSF-stimulated CD34+ progenitors (Figure 2B) compared
with freshly isolated cells (Figure 2A) was observed after 6 hours. The
fractions of CXCR3+ progenitors were 37.1%, 67.6%,
98.9%, and 99.4% after 16 hours (Figure 2C), 24 hours (Figure 2D), 36 hours (Figure 2E), and 48 hours (Figure 2F), respectively, of
stimulation with GM-CSF. CXCR3 expression was not significantly changed
in medium-cultured CD34+ progenitors compared with freshly
isolated cells at the different assessment times (data not
shown).
CXCR3 messenger RNA (mRNA) expression in CD34+ progenitors is up-regulated by GM-CSF As shown in Figure 3, mRNA of CXCR3 was detected at low levels in freshly isolated CD34+ hematopoietic progenitors from human umbilical blood. Compared with the amplification of standard DNA template (2.0 × 104 copies) with a housekeeping gene ( -actin), there were approximately 6.3 × 101 copies for CXCR3 in the tested samples
of freshly isolated CD34+ progenitors. GM-CSF stimulation
significantly up-regulated the expression of CXCR3 mRNA in
CD34+ progenitors. There were approximately
4.3 × 104 copies for CXCR3 in the tested samples of
GM-CSF-stimulated CD34+ progenitors at 36 hours, whereas
there were only about 1.6 × 102 copies for CXCR3 in the
tested samples of cultured nonstimulated CD34+ progenitors
at 36 hours (data not shown). A linear relation between CT
and the log starting quantity of standard DNA template or target cDNA
(CXCR3) was detected (data not shown). In all experiments, the
correlation coefficient was approximately 0.94. CXCR3 mRNA expression
in freshly isolated or GM-CSF-stimulated CD34+ progenitors
was confirmed by Northern blot assessment (Figure 3B). The upper panel
in Figure 3B shows that freshly isolated CD34+ progenitors
expressed CXCR3 mRNA at low levels, whereas GM-CSF-stimulated CD34+ progenitors abundantly expressed CXCR3 mRNA. The
lower panel shows that comparable total RNA amounts from different
cells were added.
IP-10 and Mig to induce chemotaxis
in GM-CSF-stimulated CD34+ progenitors and found that they
induced significant chemotactic migration in the stimulated cells. As
shown in Figure 4A (left), IP-10 and
Mig did not induce chemotactic migration in freshly isolated
CD34+ progenitors. SDF-1 was used as the positive
control because it induces a strong CD34+ progenitor
chemotactic migration. As shown in Figure 4A (right), IP-10 and Mig
induced chemotactic migration in GM-CSF-stimulated CD34+
progenitors, yielding typical bell-shaped, dose-dependent chemotaxis response curves. The optimal chemotactic concentration of both IP-10
and Mig was 100 ng/mL (56.4% ± 8.5% and 51.7% ± 9.8% of input
cells, respectively). SDF-1 , the positive control, induced a similar
GM-CSF-stimulated CD34+ progenitor chemotactic migration
(75.6% ± 9.6% of input cells). Spontaneous migration (medium
control) of different CD34+ progenitors was less then 5%
(Figure 3A). IP-10 and Mig did not induce significant chemotactic
migration of CD34+ progenitor cells cultured in medium
alone (data not shown).
To confirm that the observed GM-CSF-stimulated CD34+
progenitor chemotaxis was indeed induced by To address the question of whether enhanced migration of
GM-CSF-stimulated CD34+ progenitors toward To determine whether
IP-10 and Mig to induce
GM-CSF-stimulated CD34+ progenitor adhesion. Figure
5A shows that neither IP-10 nor Mig
induced adhesion in freshly isolated CD34+ progenitors (< 15% for both). SDF-1 was used as the positive control because it
induces a strong CD34+ progenitor adhesion (about 70%).
Figure 5B shows that IP-10 and Mig induced a strong adhesion in
GM-CSF-stimulated CD34+ progenitors. About 68% and 75%
of cells, respectively, had adhered 60 minutes after the addition of
IP-10 or Mig for (100 ng/mL). SDF-1 , the positive control,
induced a similar GM-CSF-stimulated CD34+ progenitor
adhesion (65%). IP-10 and Mig did not induce significant adhesion
of medium-cultured CD34+ progenitor cells (data not shown).
To confirm that the observed GM-CSF-stimulated CD34+
progenitor adhesion was induced by
IP-10 and Mig play an additional role in
GM-CSF-stimulated CD34+ progenitor adhesion, we performed
aggregation tests of CD34+ progenitors stimulated with
IP-10, Mig, or SDF-1 . The results shown in Figure
6 indicate that IP-10 and Mig do not
induce aggregation in freshly isolated CD34+ progenitors
(Figure 6A and 6B, scored as 0). SDF-1 was used as the positive
control because it induces a strong CD34+ progenitor
aggregation (Figure 6C, scored as 4+). IP-10 and Mig induced a
strong aggregation in GM-CSF-stimulated CD34+ progenitors
(Figure 6D, scored as 3+; and Figure 6E, scored as 2+), as did SDF-1
(Figure 6F, scored as 3+). IP-10 and Mig did not induce significant
aggregation of medium-cultured CD34+ progenitor cells (data
not shown).
To confirm that the observed GM-CSF-stimulated CD34+
progenitor aggregation was induced by Role of integrins in GM-CSF-stimulated CD34+
progenitor adhesion induced by IP-10 or
Mig. Because we had already demonstrated that IP-10 and Mig each
produced a significant induction of GM-CSF-stimulated
CD34+ progenitor adhesion and aggregation, we conducted
additional experiments to investigate whether IP-10 or Mig would
enhance the expression of integrins on GM-CSF-stimulated
CD34+ progenitors. The results of the flow cytometric
analyses shown in Figure 7 indicate that
IP-10 can significantly increase the expression of certain integrins
on GM-CSF-stimulated CD34+ progenitors. On average, there
were 32.5% ± 5.1% CD49a+ cells on GM-CSF-stimulated
CD34+ progenitors (Figure 7B), 31.5% ± 2.2%
CD49c+ cells (Figure 7C), 36.2% ± 7.8%
CD49d+ cells (Figure 7D), 42% ± 10.2% CD49e+
cells (Figure 7E), 41.5% ± 12.5% CD49f+ cells (Figure
7F), and 39% ± 7.7% CD49b+ cells (Figure 7G). After
stimulation with IP-10 (100 ng/mL) for 8 hours, the expression of
CD49a and CD49b was selectively and substantially up-regulated. On
average, there were 84% ± 2.8% CD49a+ cells on
IP-10-cultured GM-CSF-stimulated CD34+ progenitors
(Figure 7I) and 74.2% ± 4.7% CD49b+ cells (Figure 7J).
Statistical analysis for the 4 experiments showed a significant
difference in CD49a and CD49b expression in GM-CSF-stimulated
CD34+ cells compared with GM-CSF-stimulated
CD34+ cells or IP-10-stimulated CD34+ cells
(both P < .003; n = 4). On average, there were 45.7% ± 4.5% CD49c+ cells on IP-10-cultured,
GM-CSF-stimulated CD34+ progenitors (Figure 7K), 45.5% ± 4.7% CD49d+ cells (Figure 7L), 45.2% ± 3.8%
CD49e+ cells (Figure 7M), and 46.2% ± 5.1%
CD49f+ cells (Figure 7N). There was no significant
difference in CD49c, CD49d, CD49e, or CD49f cell expression in
GM-CSF-stimulated CD34+ cells compared with
GM-CSF-stimulated and IP-10-stimulated CD34+ cells
(all P > .05; n = 4). Figures 7A and 7H show the
results with isotype controls for a-CD49a and a-CD49b.
We also observed that Mig (100 ng/mL) selectively and substantially up-regulated the expression of CD49a and CD49b on GM-CSF-stimulated CD34+ progenitors (data not shown). In addition, we examined the expression of integrins on freshly isolated CD34+ hematopoietic progenitors. There was no significant difference between freshly isolated and GM-CSF-stimulated CD34+ hematopoietic progenitors in the expression of certain integrins (data not shown). Because we found a selective and substantial up-regulation of
expression of CD49a and CD49b on GM-CSF-stimulated CD34+
progenitors induced by
IP-10, Mig, or
SDF-1 . As shown in Figure 9, CXCR3 was
evenly distributed throughout the GM-CSF-stimulated CD34+
progenitors (Figure 9A). On stimulation of GM-CSF-stimulated CD34+ progenitors with IP-10 (Figure 9B) or Mig (Figure
9C), a rapid redistribution of CXCR3 took place that resulted in
movement of the receptors to the leading edge of the cells. The insets
in Figure 9 show the clusters of CXCR3 oriented in a certain direction. Figure 9D shows the CXCR3 evenly distributed throughout the
GM-CSF-stimulated CD34+ progenitors, although the cells
migrated through the gradient of SDF-1 , indicating that the
polarization of CXCR3 on the GM-CSF-stimulated CD34+
progenitors is receptor-ligand ( IP-10 and Mig) specific.
The mechanisms and specific molecules involved in the
mobilization of hematopoietic progenitor cells from the
hematopoietic organs into peripheral blood, in the homing of
hematopoietic progenitor cells, and in their trafficking through
the hematopoietic organs during maturation are unclear. Hematopoietic
progenitor cells express CXCR422 and migrate toward a
gradient of the chemotactic factor SDF-1 The function of adhesion molecules on the surface of leukocytes is critically regulated by activating events triggered by chemoattractants binding to specific receptors on the leukocytes.30 Hematopoietic progenitor cells home to the extravascular compartment of the bone marrow during transplantation. Multipotential and self-renewing hematopoietic cells migrate to the bone marrow from the fetal liver during fetal development. In the other direction, hematopoietic progenitor cells are mobilized from the bone marrow to the peripheral blood in response to injected cytokines such as GM-CSF, granulocyte colony-stimulating factor (G-CSF), and Steel factor (SLF).31 How do multiple chemoattractants cooperate in directing the migration of hematopoietic progenitor cells for homing and peripheral blood mobilization? SDF-1 and SLF were found to cooperate in attracting MO7e cells, cord blood cells, and bone marrow CD34+ cells.32 SDF-1 and SLF, along with other unidentified bone marrow chemoattractants, may be involved cooperatively in the migration of hematopoietic progenitor cells to the bone marrow and in preventing spontaneous mobilization of hematopoietic progenitor cells out of the bone marrow.32 Chemokines play a direct role in mobilization of hematopoietic stem cells, although cytokines have other functions, such as proliferation, modulation of adhesion molecules, and alteration of the blood-bone marrow barrier. For example, G-CSF and GM-CSF appear to have no chemotactic or chemokinetic effects on hematopoietic stem cells, whereas SLF, IL-3, and IL-11 have been reported to chemoattract murine hematopoietic progenitor cells.33 In the current study, we demonstrated that Our finding that Transplanted human hematopoietic cells must retain specific adhesive capacity to interact with the vascular endothelium of the bone marrow.35 Murine hematopoietic progenitor cells interact in vivo with both P-selectin and E-selectin on vascular endothelium of bone marrow.33 Optimal recruitment of hematopoietic progenitor cells to the bone marrow requires the combined action of both selectins and vascular cell adhesion molecule 1.36,37 The rolling of hematopoietic progenitor cells on bone marrow endothelium may be accompanied by a coordinated sequence of adhesive and activation events leading to cell arrest, a critical step in the successful extravasation of blood-borne cells to extravascular sites.38,39 Leukocyte function-associated molecule 1 (LFA-1) and very late antigen (VLA) 4 are constitutively expressed by cord blood CD34+ hematopoietic progenitors in inactive forms.40 LFA-1 binding to endothelial intercellular adhesion molecule 1 is the principal adhesive interaction that mediates the firm arrest of leukocytes on vascular endothelium.40-42 Murine hematopoietic progenitors roll in vivo along bone marrow microvessels that display selectins and integrins.43 SDF-1 is expressed at high levels on bone marrow endothelium and stimulates a firm integrin-dependent adhesion of circulating CD34+ progenitors to the bone marrow microvasculature.44 We demonstrated that up-regulation of In summary, we found that
We thank Gitte Pedersen, Anne Corfitz, Ulla Minuva, and Tina Mortensen for excellent technical assistance and Dr Fritz von Bülow, Institute of Anatomy, Panum Institute, University of Copenhagen, Denmark, for assistance in immunofluorescence digital confocal microscopy.
Submitted December 30, 1999; accepted April 10, 2000.
Supported by the Danish Allergy Research Center (T.J., S.Q., and A.M.), Directionen af Hovedstadens Sygehusfællensskab, Denmark (C.J.), Novo Nordisk A/S, Denmark (S.Q.), and the National Science Foundation of China (39870674).
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Tan Jinquan or Lars K. Poulsen, Laboratory of Medical Allergology, National University Hospital, 9 Blegdamsvej, DK-2200 Copenhagen Ø, Denmark; e-mail: tan{at}rh.dk or lkpallgy{at}inet.uni2.dk.
1. Trentin L, Agostini C, Facco M, et al. The chemokine receptor CXCR3 is expressed on malignant B cells and mediates chemotaxis. J Clin Invest. 1999;104:115[Medline] [Order article via Infotrieve]. 2. Cella M, Jarrossay D, Facchetti F, et al. Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon. Nat Med. 1999;5:919[Medline] [Order article via Infotrieve]. 3. Qin S, Rottman JB, Myers P, et al. The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. J Clin Invest. 1998;101:746[Medline] [Order article via Infotrieve].
4.
Weng Y, Siciliano SJ, Waldburger KE, et al.
Binding and functional properties of recombinant and endogenous CXCR3 chemokine receptors.
J Biol Chem.
1998;273:18288
5.
Soto H, Wang W, Strieter RM, et al.
The CC chemokine 6Ckine binds the CXC chemokine receptor CXCR3.
Proc Natl Acad Sci U S A.
1998;95:8205
6.
Cole KE, Strick CA, Paradis TJ, et al.
Interferon-inducible T cell
7.
Jenh CH, Cox MA, Kaminski H, et al.
Species specificity of the CC chemokine 6Ckine signaling through the CXC chemokine receptor CXCR3: human 6Ckine is not a ligand for the human or mouse CXCR3 receptors.
J Immunol.
1999;162:3765 8. Piali L, Weber C, LaRosa G, et al. The chemokine receptor CXCR3 mediates rapid and shear-resistant adhesion-induction of effector T lymphocytes by the chemokines IP10 and Mig. Eur J Immunol. 1998;28:961[Medline] [Order article via Infotrieve].
9.
Sallusto F, Lenig D, Mackay CR, Lanzavecchia A.
Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes.
J Exp Med.
1998;187:875
10.
Sgadari C, Farber JM, Angiolillo AL, et al.
Mig, the monokine induced by interferon-gamma, promotes tumor necrosis in vivo.
Blood.
1997;89:2635
11.
Caux C, Massacrier C, Vanbervliet B, et al.
CD34+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to granulocyte-macrophage colony-stimulating factor plus tumor necrosis factor alpha. II. Functional analysis.
Blood.
1997;90:1458
12.
Jinquan T, Quan S, Feili G, Larsen CG, Thestrup-Pedersen K.
Eotaxin activates T cells to chemotaxis and adhesion only if induced to express CCR3 by IL-2 together with IL-4.
J Immunol.
1999;162:4285
13.
Heid CA, Stevens J, Livak KJ, William PM.
Real time quantitative PCR.
Genome Res.
1996;6:986 14. Kruse N, Pette M, Toyka K, Rieckmann P. Quantification of cytokine mRNA expression by RT PCR in samples of previously frozen blood. J Immunol Methods. 1997;210:195[Medline] [Order article via Infotrieve].
15.
Jinquan T, Quan S, Jacobi HH, et al.
Expression of the nuclear factors of activated T cells in eosinophils: regulation by IL-4 and IL-5.
J Immunol.
1999;163:21
16.
Sica A, Saccani A, Borsatti A, et al.
Bacterial lipopolysaccharide rapidly inhibits expression of C-C chemokine receptors in human monocytes.
J Exp Med.
1997;185:969
17.
Kim CH, Broxmeyer HE.
In vitro behavior of hematopoietic progenitor cells under the influence of chemoattractants: stromal cell-derived factor-1, Steel factor, and the bone marrow environment.
Blood.
1998;91:100
18.
Broxmeyer HE, Hangoc G, Cooper S, et al.
Growth characteristics and expansion of human umbilical cord blood and estimation of its potential for transplantation in adults.
Proc Natl Acad Sci U S A.
1992;89:4109
19.
Kim CH, Pelus LM, White JR, Broxmeyer HE.
Macrophage-inflammatory protein-3 beta/EBI1-ligand chemokine/CK beta-11, a CC chemokine, is a chemoattractant with a specificity for macrophage progenitors among myeloid progenitor cells.
J Immunol.
1998;161:2580 20. Bernard G, Zoccola D, Ticchioni M, Breittmayer JP, Aussel C, Bernard A. Engagement of the CD45 molecule induces homotypic adhesion of human thymocytes through a LFA-1/ICAM-3-dependent pathway. J Immunol. 1994;152:5161[Abstract].
21.
Serrador JM, Alonso-Lebrero JL, del Pozo MA, et al.
Moesin interacts with the cytoplasmic region of intercellular adhesion molecule-3 and is redistributed to the uropod of T lymphocytes during cell polarization.
J Cell Biol.
1997;138:1409
22.
Aiuti A, Turchetto L, Cota M, et al.
Human CD34+ cells express CXCR4 and its ligand stromal cell-derived factor-1. Implications for infection by T-cell tropic human immunodeficiency virus.
Blood.
1999;94:62
23.
Aiuti A, Webb IJ, Bleul C, Springer T, Gutierrez-Ramos JC.
The chemokine SDF-1 is a chemoattractant for human CD34+ hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34+ progenitors to peripheral blood.
J Exp Med.
1997;185:111 24. Loetscher M, Loetscher P, Brass N, Meese E, Moser B. Lymphocyte-specific chemokine receptor CXCR3: regulation, chemokine binding and gene localization. Eur J Immunol. 1998;28:3696[Medline] [Order article via Infotrieve]. 25. Jenh CH, Cox MA, Kaminski H, et al. Species specificity of the CC chemokine 6Ckine signaling through the CXC chemokine receptor CXCR3: human 6Ckine is not a ligand for the human or mouse CXCR3 receptors. J Immunol. 1999;162:3765.
26.
Bonecchi R, Bianchi G, Bordignon PP, et al.
Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s.
J Exp Med.
1998;187:129 27. Sorensen TL, Tani M, Jensen J, et al. Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J Clin Invest. 1999;103:807[Medline] [Order article via Infotrieve]. 28. Sarris AH, Daliani D, Ulmer R, et al. Interferon-inducible protein 10 as a possible factor in the pathogenesis of cutaneous T-cell lymphomas. Clin Cancer Res. 1997;3:169[Abstract]. 29. Farber JM. Mig and IP-10: CXC chemokines that target lymphocytes. J Leukoc Biol. 1997;61:246[Abstract].
30.
Dieu MC, Vanbervliet B, Vicari A, et al.
Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites.
J Exp Med.
1998;188:373
31.
Donahue RE, Kirby MR, Metzger ME, et al.
Peripheral blood CD34+ cells differ from bone marrow CD34+ cells in Thy-1 expression and cell cycle status in nonhuman primates mobilized or not mobilized with colony-stimulating factor and/or stem cell factor.
Blood.
1996;87:1644
32.
Kim CH, Qu CK, Hangoc G, et al.
Abnormal chemokine-induced responses of immature and mature hematopoietic cells from motheaten mice implicate the protein tyrosine phosphatase SHP-1 in chemokine responses.
J Exp Med.
1999;190:681
33.
Okumura N, Tsuji K, Ebihara Y, et al.
Chemotactic and chemokinetic activities of stem cell factor on murine hematopoietic progenitor cells.
Blood.
1996;87:4100 34. Kim CH, Broxmeyer HE. SLC/exodus2/6Ckine/TCA4 induces chemotaxis of hematopoietic progenitor cells: differential activity of ligands of CCR7, CXCR3, or CXCR4 in chemotaxis vs. suppression of progenitor proliferation. J Leukoc Biol. 1999;66:455[Abstract].
35.
Quesenberry PJ, Becker PS.
Stem cell homing: rolling, crawling, and nesting.
Proc Natl Acad Sci U S A.
1998;95:15155
36.
Mazo IB, Gutierrez-Ramos J-C, Frenette PS, Hynes RO, Wagner DD, von Andrian UH.
Hematopoietic progenitor cell rolling in bone marrow microvessels: parallel contributions by endothelial selectins and vascular cell adhesion molecule 1.
J Exp Med.
1998;188:465
37.
Frenette PS, Subbarao S, Mazo IB, von Andrian UH, Wagner DD.
Endothelial selectins and vascular cell adhesion molecule-1 promote hematopoietic progenitor homing to bone marrow.
Proc Natl Acad Sci U S A.
1998;95:14423 38. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell. 1994;76:301[Medline] [Order article via Infotrieve]. 39. Butcher EC. Leukocyte-endothelial cell recognition: three (or more) steps to specificity and diversity. Cell. 1991;6:1033. 40. Bargatze RF, Jutila MA, Butcher EC. Distinct roles of L-selectin and integrins alpha 4 beta 7 and LFA-1 in lymphocyte homing to Peyer's patch-HEV in situ: the multistep model confirmed and refined. Immunity. 1995;3:99[Medline] [Order article via Infotrieve].
41.
Bargatze RF, Butcher EC.
Rapid G protein-regulated activation event involved in lymphocyte binding to high endothelial venules.
J Exp Med.
1993;178:367 42. Schweitzer KM, Drager AM, van der Valk P, et al. Constitutive expression of E-selectin and vascular cell adhesion molecule-1 on endothelial cells of hematopoietic tissues. Am J Pathol. 1996;148:165[Abstract].
43.
Peled A, Petit I, Kollet O, et al.
Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4.
Science.
1999;283:845 44. Peled A, Grabovsky V, Habler L, et al. The chemokine SDF-1 stimulates integrin-mediated arrest of CD34+ cells on vascular endothelium under shear flow. J Clin Invest. 1999;104:1199[Medline] [Order article via Infotrieve].
© 2000 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() |
H. Yuling, X. Ruijing, J. Xiang, J. Yanping, C. Lang, L. Li, Y. Dingping, T. Xinti, L. Jingyi, T. Zhiqing, et al. CD19+CD5+ B Cells in Primary IgA Nephropathy J. Am. Soc. Nephrol., November 1, 2008; 19(11): 2130 - 2139. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. C. Yates, D. Whaley, A. Y-Chen, P. Kulesekaran, P. A. Hebda, and A. Wells ELR-Negative CXC Chemokine CXCL11 (IP-9/I-TAC) Facilitates Dermal and Epidermal Maturation during Wound Repair Am. J. Pathol., September 1, 2008; 173(3): 643 - 652. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Bernardini, G. Sciume, D. Bosisio, S. Morrone, S. Sozzani, and A. Santoni CCL3 and CXCL12 regulate trafficking of mouse bone marrow NK cell subsets Blood, April 1, 2008; 111(7): 3626 - 3634. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Wang, H. Yuling, J. Yanping, T. Xinti, Y. Yaofang, Y. Feng, X. Ruijin, W. Li, C. Lang, L. Jingyi, et al. CCL19 and CXCL13 Synergistically Regulate Interaction between B Cell Acute Lymphocytic Leukemia CD23+CD5+ B Cells and CD8+ T Cells J. Immunol., September 1, 2007; 179(5): 2880 - 2888. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Chunsong, H. Yuling, W. Li, X. Jie, Z. Gang, Z. Qiuping, G. Qingping, Z. Kejian, Q. Li, A. E. Chang, et al. CXC Chemokine Ligand 13 and CC Chemokine Ligand 19 Cooperatively Render Resistance to Apoptosis in B Cell Lineage Acute and Chronic Lymphocytic Leukemia CD23+CD5+ B Cells J. Immunol., November 15, 2006; 177(10): 6713 - 6722. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Sen, B. Yongyi, H. Yuling, X. Luokun, H. Li, X. Jie, D. Tao, Z. Gang, L. Junyan, H. Chunsong, et al. V{alpha}24-Invariant NKT Cells from Patients with Allergic Asthma Express CCR9 at High Frequency and Induce Th2 Bias of CD3+ T Cells upon CD226 Engagement J. Immunol., October 15, 2005; 175(8): 4914 - 4926. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. B. Kwak, S. W. Lee, H. M. Jin, H. Ha, S. H. Lee, S. Takeshita, S. Tanaka, H.-M. Kim, H.-H. Kim, and Z. H. Lee Monokine induced by interferon-{gamma} is induced by receptor activator of nuclear factor {kappa}B ligand and is involved in osteoclast adhesion and migration Blood, April 1, 2005; 105(7): 2963 - 2969. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Qiuping, L. Qun, H. Chunsong, Z. Xiaolian, H. Baojun, Y. Mingzhen, L. Chengming, H. Jinshen, G. Qingping, Z. Kejian, et al. Selectively Increased Expression and Functions of Chemokine Receptor CCR9 on CD4+ T Cells from Patients with T-Cell Lineage Acute Lymphocytic Leukemia Cancer Res., October 1, 2003; 63(19): 6469 - 6477. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Jiankuo, W. Xingbing, H. Baojun, W. Xiongwin, L. Zhuoya, X. Ping, X. Yong, L. Anting, H. Chunsong, G. Feili, et al. Peptide Nucleic Acid Antisense Prolongs Skin Allograft Survival by Means of Blockade of CXCR3 Expression Directing T Cells into Graft J. Immunol., February 1, 2003; 170(3): 1556 - 1565. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. H. Dufour, M. Dziejman, M. T. Liu, J. H. Leung, T. E. Lane, and A. D. Luster IFN-{gamma}-Inducible Protein 10 (IP-10; CXCL10)-Deficient Mice Reveal a Role for IP-10 in Effector T Cell Generation and Trafficking J. Immunol., April 1, 2002; 168(7): 3195 - 3204. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. M A. El-Asrar, S. Struyf, A. A Al-Mosallam, L. Missotten, J. Van Damme, and K. Geboes Expression of chemokine receptors in vernal keratoconjunctivitis Br J Ophthalmol, November 1, 2001; 85(11): 1357 - 1361. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Jinquan, L. Anting, H. H. Jacobi, C. Glue, C. Jing, L. P. Ryder, H. O. Madsen, A. Svejgaard, P. S. Skov, H.-J. Malling, et al. CXCR3 Expression on CD34+ Hemopoietic Progenitors Induced by Granulocyte-Macrophage Colony-Stimulating Factor: II. Signaling Pathways Involved J. Immunol., October 15, 2001; 167(8): 4405 - 4413. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Copyright © 2000 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||